EirGenix Inc. is a biopharmaceutical company specializing in the development of biologics and the provision of contract development and manufacturing organization (CDMO) services. The company operates two business units: a CDMO unit supporting global partners in the development and manufacturing of biologics, and a Product Development unit focused on biosimilar and biobetter programs. EirGenix maintains cGMP-compliant manufacturing facilities certified by the U.S. FDA, EMA, PMDA, TFDA, and TGA, utilizing both mammalian and microbial platforms for production from clinical to commercial supply. Its product pipeline includes EG12014, a Trastuzumab biosimilar for breast cancer, and EG1206A, a Pertuzumab biosimilar, alongside ongoing research into antibody-drug conjugates (ADCs) and immuno-oncology biologics. The company integrates upstream and downstream process development, clinical trials, and regulatory applications, with a strategic focus on the HER2 breast cancer treatment matrix. EirGenix was founded on December 21, 2012, and engages in product licensing, co-development, and regional partnerships to expand its international presence.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage eirgenix.com
Sector Healthcare IR page —
Tags
biosimilars, monoclonal antibodies, antibody-drug conjugates, cdmo, breast cancer, her2, mammalian cell culture, microbial fermentation, oncology, EG12014, EG1206A, Trastuzumab, Pertuzumab, Herceptin, Atezolizumab, Daratumumab
Press page —

Metrics

Valuation  
Market cap NT$ 14.201B
Market cap (USD) $ 431.027M
P/E -28.53
PEG —
P/BV 1.83
P/S 9.61
P/OCF -45.60
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -8.6%
ROI -9.1%
ROIC -7.3%
Profit margin -75.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 1.005B 1.009B 1.023B 1.481B 1.697B 1.072B 476.085M 282.209M 297.866M 253.107M 102.784M
Net profit -760.552M -698.344M -915.208M -115.54M -42.581M -1.042B -860.925M -367.788M -174.855M -112.407M -134.577M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 61.7 — — — — — — — — — —
P/S 18.58 — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

更正本公司115年9月關係人交易申報資訊 Bull 0 Bear 0 Routine

Prompts

EirGenix Inc. (ticker 6589.TW), listed in Taiwan.

ETFs Holding EirGenix Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.02% 20,000 $ 32.324K Nov 16, 2026
DEXC 0.01% 13,000 $ 21.292K Nov 12, 2026
DFEM 0.00% 209,484 $ 343.109K Nov 12, 2026
DFAX 0.00% 143,000 $ 234.216K Nov 12, 2026
DFAE 0.00% 89,000 $ 145.771K Nov 12, 2026